AceReport Image
OSTEOARTHRITIS
Effect of teriparatide on vertebral fracture risk factors in osteoporosis patients
Verified
This report has been verified by one or more authors of the original publication.
Curr Med Res Opin. 2014 May;30(5):931-6

237 elderly men and postmenopausal women, between the ages of 65 and 91 years old, with primary osteoporosis with up to 5 prevalent vertebral fractures caused by low BMD of the lumbar spine, were randomly assigned into 1 of 2 groups, a treatment and a placebo, to determine the effect a once a week administration of 56.6 microgram teriparatide had on bone mineral density and bone turnover markers 72 weeks after intervention. The results of the study indicated that percentage change in lumbar bone mineral density was significantly better in the teriparatide group when compared to the placebo treatment. One incident of vertebral fracture occurred in the teriparatide group compared to 16 in the placebo group. The percentage of treatment effect that could be explained by lumbar bone mineral density was 83%, as calculated by Freeman’s method.

Unlock the full ACE Report

You have access to {0} free articles per month.
Click below to unlock and view this {1}
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
{0} of {1} free articles

Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.

Upgrade Now
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade Account
Upgrade
Search
Close Search Window
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Effect of teriparatide on vertebral fracture risk factors in osteoporosis patients. ACE Report. 2014;4(8):14. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report